NEW YORK (360Dx) – The European Union's Horizon 2020 program has awarded a €2.35 million ($2.7 million) grant for small- and medium-sized enterprises to Stockholm-based Elypta, which is developing a metabolism-based liquid biopsy platform for the detection and monitoring of cancers.
Elypta said it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its metabolism-based liquid biopsy platform for early detection of recurrent renal cell carcinoma (RCC), the most common form of kidney cancer.